Announcements Trials
Browse Landscape

Phase

Phase 2 1

Status

Unknown 1

Sponsor Class

OTHER 1

Study Type

Interventional 1

Sponsor

Cancer Type

Myeloid 1Lymphoid 1

Conditions

Myelodysplastic Syndromes 1Lymphoma 1Graft vs Host Disease 1

Interventions

Cyclophosphamide 37Etoposide 25Vincristine 24Cytarabine 21Doxorubicin 19Rituximab 17Radiotherapy 17Peripheral Blood Stem Cell Transplantation 16Melphalan 16Prednisolone 14Methotrexate 14Filgrastim 13fludarabine phosphate 11Prednisone 11Dexamethasone 11Carmustine 9Bleomycin 9pegylated granulocyte colony-stimulating factor 8Cyclosporine 8Busulfan 8fludarabine 7Ifosfamide 7Cisplatin 7sargramostim 6Vinblastine 6Mitoxantrone 6Methylprednisolone 6Gemcitabine 6Chlorambucil 6Antilymphocyte Serum 6

Date Range

30 days90 days1 yearAll

Options

Has results Has announcements

Clinical Trials

1 trials
RecentStart dateEnrollment
Unknown × Lymphoma × Maraviroc × Clear all
NCT02799888 2016-06-15

Maraviroc-Based GVHD Prophylaxis in HLA-Unrelated and HLA-Mismatched Related Transplantation

Affiliated Hospital to Academy of Military Medical Sciences

Phase 2 Unknown
40 enrolled
LymphoidMyeloid

Graft vs Host Disease, Lymphoma, Myelodysplastic Syndromes

Data powered by HemOnc (CC BY 4.0) Colophon âš¡